Latest Mymetics Corp (MYMX) Headlines
Mymetics Strengthens Virosome Vaccine Platform
Marketwire - Mon Mar 10, 7:48AM CDT
Mymetics (OTCBB: MYMX) announced today that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Astellas to Form Strategic Partnership With ClearPath To Build Vaccine Portfolio
Marketwire - Mon Jan 06, 1:12AM CST
Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013. Astellas will fund RSVC's development of a virosome vaccine technology, licensed from Mymetics Corporation (Mymetics - OTCBB: MYMX), for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof-of-concept study. Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product.
Malaria - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nj95jg/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2013" report to their offering. 'Malaria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. Scope - A snapshot of the global therapeutic scenario for Malaria. - A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malaria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Malaria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Sanofi-Aventis AstraZeneca PLC GlaxoSmithKline plc Inovio Biomedical Corporation GenVec, Inc. Novartis AG Actelion Ltd Chong Kun Dang Pharmaceutical Eisai Co., Ltd. Pfizer Inc. Ranbaxy Laboratories Limited Aduro BioTech CEL-SCI Corporation Crucell N.V. Hollis-Eden Pharmaceuticals, Inc. Immtech Pharmaceuticals, Inc. Mymetics Corporation Patrys Limited BioCryst Pharmaceuticals, Inc. IPCA Laboratories Limited Lipoxen PLC Raptor Pharmaceuticals Corp. Affitech A/S and many more... For more information visit http://www.researchandmarkets.com/research/nj95jg/malaria About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Signal Daily Stock Watch - Mymetics Corporation (OTCQB: MYMX)
WorldStockWire - Tue Sep 03, 7:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013
M2 - Tue Aug 13, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tl6fwn/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Syncytial Virus (RSV) Infections. - A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - Ablynx - Alios BioPharma, Inc. - Alnylam Pharmaceuticals, Inc - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Bavarian Nordic A/S - Celltrion, Inc. - Crucell N.V. - DBV Technologies - Functional Genetics, Inc. - GenVec, Inc. - Gilead Sciences, Inc. - iBio, Inc. - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Kineta, Inc. - LigoCyte Pharmaceuticals, Inc. - MedImmune LLC - Merus B.V. - MicroDose Therapeutx, Inc. - Mucosis B.V. - Mymetics Corporation - NanoBio Corporation - Novavax, Inc. - Okairos - Panacea Biotec Limited - Pevion Biotech Ltd - REPLICor Inc. - Romark Laboratories, L.C. - SelectX Pharmaceuticals, Inc. - Sirnaomics, Inc. - Spider Biotech S.r.l. - Symphogen A/S - Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/tl...espiratory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
HIV / AIDS - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for HIV/AIDS
M2 - Wed Aug 07, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8df3d/hiv__aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. HIV / AIDS - Pipeline Review. Scope - A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV / AIDS pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Achillion Pharmaceuticals, Inc. Boehringer Ingelheim GmbH CONRAD Cellectis S.A. Esteve Group F. Hoffmann-La Roche Ltd. GeneCure LLC GlaxoSmithKline plc Heat Biologics, Inc. iCo Therapeutics Inc. ImQuest Life Sciences Johnson & Johnson Kainos Medicine, Inc. Koronis Pharmaceuticals, Inc. Laila Pharmaceuticals Pvt. Ltd. Medivir AB Merck & Co., Inc. Mymetics Corporation Novartis AG OyaGen Inc. PTC Therapeutics, Inc. Pfizer Inc. Pharmsynthez Sanofi-Aventis SuperGen, Inc. TVAX Biomedical, LLC Transgene Biotek Ltd United Biomedical, Inc. Viral Genetics, Inc. Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/d8df3d/hiv__aids About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Data Published in PLOS ONE Show Mymetics' HIV-1 Innovative Vaccine is Safe and Elicits Strong Immunogenicity
Marketwire - Thu Feb 21, 1:31AM CST
Results from a randomized study published in PLOS ONE(1) today demonstrate that Mymetic' innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation (OTCBB: MYMX) is a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense, to prevent transmission of infectious diseases.
Mymetics Strengthens Virosome Vaccine Platform
Marketwire - Mon Mar 10, 7:48AM CDT
Mymetics (OTCBB: MYMX) announced today that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP.
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Astellas to Form Strategic Partnership With ClearPath To Build Vaccine Portfolio
Marketwire - Mon Jan 06, 1:12AM CST
Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013. Astellas will fund RSVC's development of a virosome vaccine technology, licensed from Mymetics Corporation (Mymetics - OTCBB: MYMX), for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof-of-concept study. Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product.
Malaria - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nj95jg/malaria) has announced the addition of the "Malaria - Pipeline Review, H2 2013" report to their offering. 'Malaria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. Scope - A snapshot of the global therapeutic scenario for Malaria. - A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malaria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Malaria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Genzyme Corporation Sanofi-Aventis AstraZeneca PLC GlaxoSmithKline plc Inovio Biomedical Corporation GenVec, Inc. Novartis AG Actelion Ltd Chong Kun Dang Pharmaceutical Eisai Co., Ltd. Pfizer Inc. Ranbaxy Laboratories Limited Aduro BioTech CEL-SCI Corporation Crucell N.V. Hollis-Eden Pharmaceuticals, Inc. Immtech Pharmaceuticals, Inc. Mymetics Corporation Patrys Limited BioCryst Pharmaceuticals, Inc. IPCA Laboratories Limited Lipoxen PLC Raptor Pharmaceuticals Corp. Affitech A/S and many more... For more information visit http://www.researchandmarkets.com/research/nj95jg/malaria About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Signal Daily Stock Watch - Mymetics Corporation (OTCQB: MYMX)
WorldStockWire - Tue Sep 03, 7:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013
M2 - Tue Aug 13, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tl6fwn/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Syncytial Virus (RSV) Infections. - A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - Ablynx - Alios BioPharma, Inc. - Alnylam Pharmaceuticals, Inc - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Bavarian Nordic A/S - Celltrion, Inc. - Crucell N.V. - DBV Technologies - Functional Genetics, Inc. - GenVec, Inc. - Gilead Sciences, Inc. - iBio, Inc. - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Kineta, Inc. - LigoCyte Pharmaceuticals, Inc. - MedImmune LLC - Merus B.V. - MicroDose Therapeutx, Inc. - Mucosis B.V. - Mymetics Corporation - NanoBio Corporation - Novavax, Inc. - Okairos - Panacea Biotec Limited - Pevion Biotech Ltd - REPLICor Inc. - Romark Laboratories, L.C. - SelectX Pharmaceuticals, Inc. - Sirnaomics, Inc. - Spider Biotech S.r.l. - Symphogen A/S - Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/tl...espiratory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
HIV / AIDS - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for HIV/AIDS
M2 - Wed Aug 07, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8df3d/hiv__aids) has announced the addition of the "HIV / AIDS - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'HIV / AIDS - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. HIV / AIDS - Pipeline Review. Scope - A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV / AIDS pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Achillion Pharmaceuticals, Inc. Boehringer Ingelheim GmbH CONRAD Cellectis S.A. Esteve Group F. Hoffmann-La Roche Ltd. GeneCure LLC GlaxoSmithKline plc Heat Biologics, Inc. iCo Therapeutics Inc. ImQuest Life Sciences Johnson & Johnson Kainos Medicine, Inc. Koronis Pharmaceuticals, Inc. Laila Pharmaceuticals Pvt. Ltd. Medivir AB Merck & Co., Inc. Mymetics Corporation Novartis AG OyaGen Inc. PTC Therapeutics, Inc. Pfizer Inc. Pharmsynthez Sanofi-Aventis SuperGen, Inc. TVAX Biomedical, LLC Transgene Biotek Ltd United Biomedical, Inc. Viral Genetics, Inc. Wittycell S.A.S. For more information visit http://www.researchandmarkets.com/research/d8df3d/hiv__aids About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Data Published in PLOS ONE Show Mymetics' HIV-1 Innovative Vaccine is Safe and Elicits Strong Immunogenicity
Marketwire - Thu Feb 21, 1:31AM CST
Results from a randomized study published in PLOS ONE(1) today demonstrate that Mymetic' innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation (OTCBB: MYMX) is a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense, to prevent transmission of infectious diseases.
